ArticleWorld journal of gastrointestinal oncology2024
Systematic review of risk factors, prognosis, and management of colorectal signet-ring cell carcinoma.
Article in World journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Primary Signet Ring Cell Adenocarcinoma of the Appendix Masquerading as Acute Appendicitis: A Diagnostic Pitfall.Iranian journal of pathology · 2026Article
- Young-onset signet ring cell colorectal adenocarcinoma: demographics, clinicopathological profile, and survival analysis.Proceedings (Baylor University. Medical Center) · 2026Article
- Article
- Primary colonic signet-ring cell carcinoma in an elderly patient: a rare case report.International journal of surgery case reports · 2026Article
- Construction and testing of a nomogram for patients with pancreatic signet-ring cell carcinoma and analysis of treatment-related survival differences: a study based on the Surveillance, Epidemiology, and End Results (SEER) database.Translational cancer research · 2026Article
- Article
- Development and validation of machine learning models for predicting cancer-specific survival in colorectal signet ring cell carcinoma.BMC gastroenterology · 2026Article
- Clinicopathological Features and Prognostic Impact of Colorectal Signet-Ring Cell Carcinoma: The Prognostic Impact of Metastatic Lymph Node Histology.Journal of the anus, rectum and colon · 2026Article
- Clinicopathological features and prognosis of patients with colorectal Mucinous adenocarcinoma mixed with other pathological components: a nationwide retrospective study in China.Techniques in coloproctology · 2025Article
- Colorectal Cancer in Elderly Patients: Insights into Presentations, Prognosis, and Patient Outcomes.Medicina (Kaunas, Lithuania) · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal signet-ring cell carcinoma (CSRCC) is a rare clinical entity which accounts for approximately 1% of all colorectal cancers. Although multiple studies concerning this specific topic have been published in the past decades, the pathogenesis, associated risk factors, and potential implications on treatment are still poorly understood. Besides the low incidence, historically confusing histological criteria have resulted in confusing data. Nevertheless, the rising incidence of CSRCC along with relatively young age at presentation and associated dismal prognosis, highlight the actual interest to synthesize the known literature regarding CSRCC.
aimTo provide an updated overview of risk factors, prognosis, and management of CSRCC.
methodsA literature search in the MEDLINE/PubMed database was conducted with the following search terms used: 'Signet ring cell carcinoma' and 'colorectal'. Studies in English language, published after January 1980, were included. Studies included in the qualitative synthesis were evaluated for content concerning epidemiology, risk factors, and clinical, diagnostic, histological, and molecular features, as well as metastatic pattern and therapeutic management. If possible, presented data was extracted in order to present a more detailed overview of the literature.
resultsIn total, 67 articles were included for qualitative analysis, of which 54 were eligible for detailed data extraction. CSRCC has a reported incidence between 0.1%-2.4% and frequently presents with advanced disease stage at the time of diagnosis. CSRCC is associated with an impaired overall survival (5-year OS: 0%-46%) and a worse stage-corrected outcome compared to mucinous and not otherwise specified adenocarcinoma. The systematic use of exploratory laparoscopy to determine the presence of peritoneal metastases has been advised. Surgery is the mainstay of treatment, although the rates of curative resection in CSRCC (21%-82%) are lower compared to those in other histological types. In case of peritoneal metastasis, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy should only be proposed in selected patients.
conclusionCSRCC is a rare clinical entity most often characterized by young age and advanced disease at presentation. As such, diagnostic modalities and therapeutic approach should be tailored accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.